USA flag logo/image

An Official Website of the United States Government

HIGH THROUGHPUT CLONING OVEREXPRESSION AND PURIFICATION OF ACTIVE MEMBRANE PROT

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85885
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
MH081380
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
LUCIGEN CORPORATION
2905 PARMENTER ST. Middleton, WI 53562-2547
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: HIGH THROUGHPUT CLONING OVEREXPRESSION AND PURIFICATION OF ACTIVE MEMBRANE PROT
Agency: HHS
Contract: 1R43MH081380-01
Award Amount: $250,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Functional analysis of proteins is essential to thoroughly understand the basic interactions essential for life. However, obtaining pure proteins for basic research and drug screening is limited by technical bottlenecks . For example, high throughput studies are severely hampered by difficulties in producing and detecting active proteins, especially those that are bound to cellular membranes. Only a small fraction of known proteins have been thoroughly characterized. Of t hese the vast majority are soluble proteins. Although membrane proteins may constitute a third of the genes in an organism, they represent only 0.5% of the 3D protein structures that have been deciphered. We propose a system to allow robust production and isolation of proteins in a soluble, fully functional form. It will be particularly well-suited to analysis of membrane proteins, and it will be amenable to screening for active membrane proteins in a large-scale format. We plan to make use of novel cloning vectors that stably maintain otherwise unclonable genes. A new E. coli cell line will be developed that produces recombinant membrane proteins in easily-purified vesicles. This system will also incorporate a new affinity capture reagent that yields acti ve, undenatured protein with 95% purity. In Phase II, we plan to extend this technology to facilitate expression of the most difficult proteins. Novel expression vectors, cell lines, and purification reagents will be developed into individual products and complete kits. These products will enable researchers to study a wide variety of soluble or membrane- bound proteins that otherwise would be difficult or impossible to produce. This technology will have nearly universal applications in biotechnology, inclu ding critical importance in pharmaceutical research (antimicrobials, immunity, inflammation) and environmental research (biofilms, microbial energy production). An improved understanding of the structure and function of membrane proteins in prokaryotes and eukaryotes could result in significant benefits for human and animal health. For example, the ability to express pharmaceutically relevant membrane proteins, such as ion channels and G protein-coupled receptors, in an active state could lead to new therap ies for numerous diseases. Many cancer therapeutics become ineffective due to the emergence of multidrug efflux proteins in the cell membrane, and an improved understanding of these proteins could result in improved cancer therapies.

Principal Investigator:

David A. Mead
6088319011
DMEAD@LUCIGEN.COM

Business Contact:

Mead
dmead@lucigen.com
Small Business Information at Submission:

LUCIGEN CORPORATION
2120 W. GREENVIEW DR. SUITE 9 MIDDLETON, WI 53562

EIN/Tax ID: 391923306
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No